Shang Lin to Prognosis
This is a "connection" page, showing publications Shang Lin has written about Prognosis.
Connection Strength
0.048
-
COVID-19 and Oncology: Service transformation during pandemic. Cancer Med. 2020 10; 9(19):7161-7171.
Score: 0.026
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.011
-
Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol. 2007 Nov; 178(5):1925-8.
Score: 0.011